EA019331B1 - Получение налмефена гидрохлорида из налтрексона - Google Patents
Получение налмефена гидрохлорида из налтрексона Download PDFInfo
- Publication number
- EA019331B1 EA019331B1 EA201171461A EA201171461A EA019331B1 EA 019331 B1 EA019331 B1 EA 019331B1 EA 201171461 A EA201171461 A EA 201171461A EA 201171461 A EA201171461 A EA 201171461A EA 019331 B1 EA019331 B1 EA 019331B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- nalmefene
- naltrexone
- mixture obtained
- methyltriphenylphosphonium
- salt
- Prior art date
Links
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 title claims abstract description 34
- 229960003086 naltrexone Drugs 0.000 title claims abstract description 33
- GYWMRGWFQPSQLK-OPHZJPRHSA-N (4r,4as,7as,12bs)-3-(cyclopropylmethyl)-7-methylidene-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol;hydron;chloride Chemical compound Cl.N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 GYWMRGWFQPSQLK-OPHZJPRHSA-N 0.000 title claims abstract description 15
- 229960000677 nalmefene hydrochloride Drugs 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title description 12
- 238000000034 method Methods 0.000 claims abstract description 65
- 229960005297 nalmefene Drugs 0.000 claims description 65
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 claims description 62
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 49
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 44
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims description 44
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims description 30
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 28
- 239000002904 solvent Substances 0.000 claims description 25
- 239000000243 solution Substances 0.000 claims description 24
- 238000007239 Wittig reaction Methods 0.000 claims description 23
- 239000007787 solid Substances 0.000 claims description 20
- AZFQCTBZOPUVOW-UHFFFAOYSA-N methyl(triphenyl)phosphanium Chemical class C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 AZFQCTBZOPUVOW-UHFFFAOYSA-N 0.000 claims description 14
- 239000012074 organic phase Substances 0.000 claims description 13
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 12
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 239000003960 organic solvent Substances 0.000 claims description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 7
- 238000002955 isolation Methods 0.000 claims description 7
- 150000002576 ketones Chemical class 0.000 claims description 7
- LSEFCHWGJNHZNT-UHFFFAOYSA-M methyl(triphenyl)phosphanium;bromide Chemical group [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 LSEFCHWGJNHZNT-UHFFFAOYSA-M 0.000 claims description 7
- 239000011574 phosphorus Substances 0.000 claims description 7
- 229910052698 phosphorus Inorganic materials 0.000 claims description 7
- 235000019270 ammonium chloride Nutrition 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 4
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 3
- 150000008282 halocarbons Chemical class 0.000 claims description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 150000002170 ethers Chemical class 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 230000008020 evaporation Effects 0.000 claims description 2
- 239000007789 gas Substances 0.000 claims description 2
- 238000001953 recrystallisation Methods 0.000 claims description 2
- 238000010790 dilution Methods 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- QRPRIOOKPZSVFN-UHFFFAOYSA-M methyl(triphenyl)phosphanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 QRPRIOOKPZSVFN-UHFFFAOYSA-M 0.000 claims 1
- JNMIXMFEVJHFNY-UHFFFAOYSA-M methyl(triphenyl)phosphanium;iodide Chemical compound [I-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 JNMIXMFEVJHFNY-UHFFFAOYSA-M 0.000 claims 1
- 229950010675 nalmefene hydrochloride dihydrate Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 8
- 239000000047 product Substances 0.000 description 21
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 239000002585 base Substances 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- -1 hydrochloride Chemical class 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 239000006227 byproduct Substances 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 208000007848 Alcoholism Diseases 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 239000012458 free base Substances 0.000 description 5
- 239000012362 glacial acetic acid Substances 0.000 description 5
- AUONHKJOIZSQGR-UHFFFAOYSA-N oxophosphane Chemical compound P=O AUONHKJOIZSQGR-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 201000007930 alcohol dependence Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- XYDYWTJEGDZLTH-UHFFFAOYSA-N methylenetriphenylphosphorane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=C)C1=CC=CC=C1 XYDYWTJEGDZLTH-UHFFFAOYSA-N 0.000 description 4
- 150000004714 phosphonium salts Chemical class 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 206010012335 Dependence Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000012456 homogeneous solution Substances 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229940127450 Opioid Agonists Drugs 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 239000003401 opiate antagonist Substances 0.000 description 2
- MPQXHAGKBWFSNV-UHFFFAOYSA-N oxidophosphanium Chemical class [PH3]=O MPQXHAGKBWFSNV-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 208000001613 Gambling Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 229940123257 Opioid receptor antagonist Drugs 0.000 description 1
- 206010034158 Pathological gambling Diseases 0.000 description 1
- 101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- KXADPELPQCWDHL-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1.COC1=CC=CC=C1 KXADPELPQCWDHL-UHFFFAOYSA-N 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 108700023159 delta Opioid Receptors Proteins 0.000 description 1
- 102000048124 delta Opioid Receptors Human genes 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 238000006772 olefination reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 150000003018 phosphorus compounds Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- HRQDCDQDOPSGBR-UHFFFAOYSA-M sodium;octane-1-sulfonate Chemical compound [Na+].CCCCCCCCS([O-])(=O)=O HRQDCDQDOPSGBR-UHFFFAOYSA-M 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200900650 | 2009-05-25 | ||
| PCT/DK2010/050110 WO2010136039A1 (en) | 2009-05-25 | 2010-05-21 | Preparation of nalmefene hydrochloride from naltrexone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201171461A1 EA201171461A1 (ru) | 2012-05-30 |
| EA019331B1 true EA019331B1 (ru) | 2014-02-28 |
Family
ID=43222172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201171461A EA019331B1 (ru) | 2009-05-25 | 2010-05-21 | Получение налмефена гидрохлорида из налтрексона |
Country Status (35)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2712232C1 (ru) * | 2018-10-05 | 2020-01-27 | Федеральное государственное унитарное предприятие "Научно-исследовательский институт гигиены, профпатологии и экологии человека" Федерального медико-биологического агентства | Улучшенный способ получения налмефена из налтрексона |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2802295C (en) | 2010-06-11 | 2016-09-20 | Rhodes Technologies | Transition metal-catalyzed processes for the preparation of n-allyl compounds and use thereof |
| HRP20170379T1 (hr) | 2010-11-05 | 2017-05-05 | H. Lundbeck A/S | Postupak proizvodnje naltreksona |
| CN103012416B (zh) * | 2011-09-28 | 2015-07-01 | 辽宁海思科制药有限公司 | 一种盐酸纳美芬的制备方法 |
| TWI560170B (en) * | 2011-12-06 | 2016-12-01 | Lundbeck & Co As H | Process for recovery of nalmefene hydrochloride |
| CN102584840A (zh) * | 2011-12-28 | 2012-07-18 | 南京优科生物医药有限公司 | 一种制备纳美芬化合物的方法 |
| WO2013164383A1 (en) | 2012-05-03 | 2013-11-07 | H. Lundbeck A/S | Method for the manufacturing of naltrexone |
| US20140005216A1 (en) | 2012-06-27 | 2014-01-02 | H. Lundbeck A/S | Nalmefene for reduction of alcohol consumption in specific target populations |
| CN103204859B (zh) * | 2013-04-25 | 2015-12-02 | 四川海思科制药有限公司 | 一种盐酸纳美芬化合物及其制备方法 |
| AR096851A1 (es) | 2013-07-11 | 2016-02-03 | H Lundbeck As | Sales que no forman hidratos ni solvatos de nalmefeno |
| JP6448645B2 (ja) | 2013-12-20 | 2019-01-09 | ハー・ルンドベック・アクチエゼルスカベット | メランコリアの特徴を伴う抑うつ障害を処置するための、カッパ−活性を伴うオピオイド受容体拮抗薬およびボルチオキセチンの使用 |
| SG10201809280PA (en) | 2014-04-22 | 2018-11-29 | Otsuka Pharma Co Ltd | Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders |
| CN104513251A (zh) * | 2014-11-28 | 2015-04-15 | 安徽悦康凯悦制药有限公司 | 一种盐酸纳美芬的制备方法 |
| US9757372B2 (en) * | 2015-03-25 | 2017-09-12 | Taiwanj Pharmaceuticals Co., Ltd. | Toll-like receptor 4 antagonists and use in autoimmune liver diseases |
| US10927121B1 (en) | 2019-12-20 | 2021-02-23 | Southwest Research Institute | Technologies for removing residual solvent from nalmefene hydrochloride and producing crystalline nalmefene hydrochloride monohydrate, monosolvate, or crystalline nalmefene hydrochloride dihydrate |
| CA3196369A1 (en) | 2020-11-02 | 2022-05-05 | C. Frederick M. Huntley | Process for purifying noroxymorphone |
| US20240109907A1 (en) | 2021-01-28 | 2024-04-04 | Rhodes Technologies | Process for crystallizing nalmefene hydrochloride |
| CN117843650A (zh) * | 2023-12-27 | 2024-04-09 | 南京海纳医药科技股份有限公司 | 一种盐酸纳美芬的精制方法 |
| CN117986261B (zh) * | 2024-04-02 | 2024-06-18 | 成都瑞尔医药科技有限公司 | 一种盐酸纳美芬母液的回收套用方法 |
| CN119080788A (zh) * | 2024-08-19 | 2024-12-06 | 南京海鲸药业股份有限公司 | 一种盐酸纳美芬杂质的去除监控系统及去除方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0039066A2 (en) * | 1980-04-28 | 1981-11-04 | E.I. Du Pont De Nemours And Company | 17-Substituted 6-desoxy-7,8-dihydro-6-alpha-methylnoroxymorphone narcotic antagonists |
| US4535157A (en) * | 1983-11-01 | 1985-08-13 | Key Pharmaceuticals, Inc. | Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone |
| US4751307A (en) * | 1985-01-17 | 1988-06-14 | Mallinckrodt, Inc. | Wittig-reaction processes |
| EP0352025A2 (en) * | 1988-07-22 | 1990-01-24 | Baker Cummins Pharmaceuticals, Inc. | Use of nalmefene in the treatment of allergic rhinitis |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4341764A (en) | 1980-03-05 | 1982-07-27 | Cutter Laboratories, Inc. | Method of preparing fibronectin and antihemophilic factor |
| US7687646B2 (en) | 2006-03-28 | 2010-03-30 | Azad Pharmaceutical Ingredients, Ag | Polymorphic forms of olopatadine hydrochloride and methods for producing olopatadine and salts thereof |
| GB2447013A (en) * | 2007-03-01 | 2008-09-03 | Reckitt Benckiser Healthcare | Analgesic composition containing buprenorphone and nalmefene |
-
2010
- 2010-05-21 HR HRP20160110TT patent/HRP20160110T1/hr unknown
- 2010-05-21 BR BRPI1010975-7A patent/BRPI1010975B1/pt not_active IP Right Cessation
- 2010-05-21 KR KR1020117028079A patent/KR101716522B1/ko not_active Expired - Fee Related
- 2010-05-21 MY MYPI2011005679A patent/MY158251A/en unknown
- 2010-05-21 UA UAA201114599A patent/UA106752C2/uk unknown
- 2010-05-21 ES ES10720257.4T patent/ES2564006T3/es active Active
- 2010-05-21 SI SI201031133A patent/SI2435439T1/sl unknown
- 2010-05-21 MX MX2011012502A patent/MX2011012502A/es active IP Right Grant
- 2010-05-21 ME MEP-2016-40A patent/ME02622B/me unknown
- 2010-05-21 GE GEAP201012510A patent/GEP20146190B/en unknown
- 2010-05-21 JP JP2012512208A patent/JP5794980B2/ja active Active
- 2010-05-21 CN CN201080033670.3A patent/CN102459276B/zh not_active Expired - Fee Related
- 2010-05-21 DK DK10720257.4T patent/DK2435439T3/en active
- 2010-05-21 RS RS20160137A patent/RS54599B1/sr unknown
- 2010-05-21 SG SG2011086501A patent/SG176205A1/en unknown
- 2010-05-21 PL PL10720257T patent/PL2435439T3/pl unknown
- 2010-05-21 MA MA34465A patent/MA33368B1/fr unknown
- 2010-05-21 CA CA2763093A patent/CA2763093C/en active Active
- 2010-05-21 EP EP10720257.4A patent/EP2435439B8/en active Active
- 2010-05-21 HU HUE10720257A patent/HUE026892T2/en unknown
- 2010-05-21 US US13/321,597 patent/US8598352B2/en active Active
- 2010-05-21 EA EA201171461A patent/EA019331B1/ru not_active IP Right Cessation
- 2010-05-21 AU AU2010252392A patent/AU2010252392B2/en not_active Ceased
- 2010-05-21 NZ NZ596988A patent/NZ596988A/xx not_active IP Right Cessation
- 2010-05-21 WO PCT/DK2010/050110 patent/WO2010136039A1/en not_active Ceased
- 2010-05-24 TW TW99116496A patent/TWI469985B/zh not_active IP Right Cessation
- 2010-05-26 AR ARP100101818A patent/AR076891A1/es unknown
-
2011
- 2011-11-17 IL IL216422A patent/IL216422A/en not_active IP Right Cessation
- 2011-11-21 TN TNP2011000590A patent/TN2011000590A1/en unknown
- 2011-11-22 CR CR20110612A patent/CR20110612A/es unknown
- 2011-11-23 DO DO2011000362A patent/DOP2011000362A/es unknown
- 2011-11-24 ZA ZA2011/08659A patent/ZA201108659B/en unknown
- 2011-11-24 CL CL2011002974A patent/CL2011002974A1/es unknown
- 2011-11-25 CO CO11162008A patent/CO6470832A2/es active IP Right Grant
-
2016
- 2016-02-26 SM SM201600061T patent/SMT201600061B/it unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0039066A2 (en) * | 1980-04-28 | 1981-11-04 | E.I. Du Pont De Nemours And Company | 17-Substituted 6-desoxy-7,8-dihydro-6-alpha-methylnoroxymorphone narcotic antagonists |
| US4535157A (en) * | 1983-11-01 | 1985-08-13 | Key Pharmaceuticals, Inc. | Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone |
| US4751307A (en) * | 1985-01-17 | 1988-06-14 | Mallinckrodt, Inc. | Wittig-reaction processes |
| EP0352025A2 (en) * | 1988-07-22 | 1990-01-24 | Baker Cummins Pharmaceuticals, Inc. | Use of nalmefene in the treatment of allergic rhinitis |
Non-Patent Citations (2)
| Title |
|---|
| DAVID F. AYCOCK: "Solvent Applications of 2-Methyltetrahydrofuran in Organometallic and Biphasic Reactions". ORGANIC PROCESS RESEARCH & DEVELOPMENT, vol. 11, no. 1, 6 December 2006 (2006-12-06), pages 156-159, XP002596963, DOI: 10.1021/op060155c, the whole document * |
| HAHN ELLIOT F. ET AL.: "Narcotic antagonists. 4. Carbon-6 derivatives of N-substituted noroxymorphones as narcotic antagonists". JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US LNKD-DOI:10.1021/JM00237A008, vol. 18, no. 3, 1 January 1975 (1975-01-01), pages 259-262, XP002500023, ISSN: 0022-2623, Conversion of Naltrexone to Nalmefene with Ylide generated from [Ph3P-Me]+Br- and NaH in DMSO; page 260; example IIb * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2712232C1 (ru) * | 2018-10-05 | 2020-01-27 | Федеральное государственное унитарное предприятие "Научно-исследовательский институт гигиены, профпатологии и экологии человека" Федерального медико-биологического агентства | Улучшенный способ получения налмефена из налтрексона |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA019331B1 (ru) | Получение налмефена гидрохлорида из налтрексона | |
| US8530495B2 (en) | Nalmefene hydrochloride dihydrate | |
| JP6086925B2 (ja) | ナルメフェン塩酸塩の回収方法 | |
| JP2019031524A (ja) | ナルメフェン塩酸塩二水和物 | |
| HK1170728B (en) | Preparation of nalmefene hydrochloride from naltrexone | |
| HK1170728A (en) | Preparation of nalmefene hydrochloride from naltrexone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM KG MD TJ TM |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AZ BY KZ RU |